Gilgamesh Pharma
gilgameshpharmaceutical.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$60M
1 round on record
Latest round
$60M
Series A · Mar 2026 · 6 mo ago
Team
51-200
employees, estimated range
Backers
2
Y Combinator, James Beshara
The money's age
Fresh money
6 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Mar 2026 | $60M | — | PRNewswire |
Backed byfrom the funds' portfolios and accelerator catalogs
Y Combinator 
James Beshara Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Creating breakthroughs in mental health. We are on a mission to transform patient outcomes by developing rapid-acting, durable and…
Developing Rapid-Acting Treatments For Neuropsychiatric Diseases.
Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics…
Metabolic Psychiatry Labs provides advanced mental health treatment using metabolic therapy and innovative psychiatry research.
We’re building a pipeline of next-generation therapeutics focused on broadening the treatment paradigm for migraine and other headache…
Extended-release RNA medicines that turn transient treatments into durable therapies for chronic disease. ScionxBio uses synthetic…
News
Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies
/PRNewswire/ -- Gilgamesh Pharma, a clinical-stage neuroscience company developing breakthrough therapies for psychiatric and neurological disorders, today...
Read more
Report
Gilgamesh Pharma Announces Positive Topline Phase 2a Results for Blixeprodil (GM-1020) in Major Depressive Disorder
Read more
Report
Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD)
GM-2505, a novel 5-HT2A receptor agonist and 5-HT releaser, demonstrated rapid, robust, and durable antidepressant effect in MDD Demonstrated robust...
Read more
Report
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
/PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation...
Read more
Report
Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 in Major Depressive Disorder
/PRNewswire/ -- Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for central...
Read more
Report
Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder
/PRNewswire/ -- Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for mental...
Read more
Report
Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM-2505
/PRNewswire/ -- Gilgamesh Pharmaceuticals, a clinical-stage neuroscience biotech developing best-in-class medicines to redefine mental healthcare, announces...
Read more
Report
Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020
/PRNewswire/ -- Gilgamesh Pharma, a cutting-edge clinical-stage biotechnology company proudly announces the successful completion of its Phase 1 Single...
Read more
Report
Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments
/PRNewswire/ -- Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other...
Read more
Report
Financials
Total raised
$60M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2026 | $60M | Details |